A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

Trial Details

NCT ID
NCT07213674
Phase
PHASE3
Sponsor
Amgen
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Xaluritamig
  • Abiraterone acetate
  • Docetaxel
  • Cabazitaxel
Locations (sample)
  • Goodyear, Arizona, United States|33.43532,-112.35821
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Duarte, California, United States|34.13945,-117.97729
  • Duarte, California, United States|34.13945,-117.97729
  • Fullerton, California, United States|33.87029,-117.92534

Key Eligibility Criteria

  • Participant has provided informed consent before initiation of any study-specific activities/procedures.
  • Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent.
  • Participant must have histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate. Mixed histologies (eg, adenoca…
  • Metastatic castration-resistant prostate cancer (mCRPC) with ≥ 1 metastatic lesion that is present on baseline computed tomography (CT), magnetic r…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →